search
Back to results

Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF

Primary Purpose

Dupuytren Contracture

Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Xiapex
Needle aponeurotomy
Sponsored by
University Hospital, Akershus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dupuytren Contracture focused on measuring Primary Dd disase, MCP joint

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Primary Dd disease (no earlier treatment for this condition of the hand involved)
  • Single digit involvement, one of the three ulnar digits
  • Average norwegian language skills.
  • MCPJ contracture of 30 degrees or more and less than 20 degree involvement of the adjacent PIPJ
  • Minimum 18 y.o.

Exclusion Criteria:

  • Involvement of 2 fingers/joints
  • Earlier treatment for Dd disease of the same hand, affection of addjecent PIPJ of 20 degrees or mor
  • Pregnancy
  • Ongoing treatment with platelet inhibitors
  • Treatment with tetracycline 2 weeks prior to treatment date
  • Poor norwegian language skills
  • Participation in other studies 4 weeks prior or after treatment date
  • "Need to treat" of both hands

Sites / Locations

  • Akershus University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Needle aponeurotomy

Xiapex

Arm Description

percutaneous transection or pretendinous palmar dupytren cord

Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord

Outcomes

Primary Outcome Measures

Reduction in Total Passive Extension Deficit

Secondary Outcome Measures

Quick Dash (Disabilities of the shoulder and Hand)
EQ5D (Euroqol 5 Dimensions)
Brief MHQ (Michigan Hand Questionare)
URAM (Unité Rhumatologique des Affections de la Main)
Jamar grip strength
VAS (Visual analogue scale) pain
0 is no pain, 10 maximum pain
VAS (Visual analogue sale) satisfaction
0 is not satisfied, 10 maximum satisfied
Complications
AE,SAE,SUSAR
Recurrence
def. 30 degrees of treated MCP joint, or 20 or more degrees of adjecent PIPJ

Full Information

First Posted
December 29, 2015
Last Updated
April 19, 2022
Sponsor
University Hospital, Akershus
search

1. Study Identification

Unique Protocol Identification Number
NCT02647619
Brief Title
Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF
Official Title
A Randomized Controlled Trial (RCT) Comparing Clostridium Histolyticum With Needle Aponeurotomy.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
October 2013 (Actual)
Primary Completion Date
April 2022 (Actual)
Study Completion Date
April 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Akershus

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aim: Clinical RCT comparing functional results and recurrence rate following enzymatic treatment vs. needle aponeurotomy. Materials and methods: 30° or more contracture of only one metacarpophalangeal (MCP) joint contracture of one of the three ulnar digits and less than 20° for the adjacent proximal interphalangeal (PIP) joint. Patients with primary disease of the hand. Total of 80 patients needed to detect difference of 13.5°. 1) Needle aponeurotomy 2) Clostridium Histolyticum treatment. Clinical follow ups 1,4 weeks, 16 weeks and 1,2 and 5 years. Functional outcome scores: URAM, Quick Dash, EQ5D, brief MHQ, VAS pain and VAS patient satisfaction. Total passive extension contracture reduction, recurrence rate and registration of complications.
Detailed Description
Open surgery (fascieectomy) has traditionally been considered the gold standard of treatment for Dupytren´s disease (Dd) despite considerable risk of complications. There is an increasing interest in Scandinavia in the treatment of Dd with Clostridium Histolyticum (Xiapex ®, Auxillium). However the enzyme is expensive and long-term effects are not well documented. More studies are needed to analyze both short and long term clinical outcome as well as cost-benefit analysis. The treatment arm of Xiapex in this study follows the recommendation as by the producer. The other treatment of Dd contracture in this study is needle fasiotomy/aponeurotomy. We use multiple perforation technigue with 26 G needle needle, with as little local anesthesia (xylocin w adrenaline) as needed during contionus extension of the finger untill successfully extended. The two procedures leave little scar tissue lessening the challenges posed by the reoperations. Recurrence rate of contracture following different treatments of Dupuytren's disease differs widely in the literature, and the rate is influenced by multiple factors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dupuytren Contracture
Keywords
Primary Dd disase, MCP joint

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Needle aponeurotomy
Arm Type
Active Comparator
Arm Description
percutaneous transection or pretendinous palmar dupytren cord
Arm Title
Xiapex
Arm Type
Active Comparator
Arm Description
Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
Intervention Type
Drug
Intervention Name(s)
Xiapex
Other Intervention Name(s)
Xiaflex
Intervention Description
Injection of collagenase of primary dupytren cord
Intervention Type
Procedure
Intervention Name(s)
Needle aponeurotomy
Other Intervention Name(s)
Percutaneous needle fasiotomy
Intervention Description
26 G needle multiple perforation tecqnique with local anesthetic
Primary Outcome Measure Information:
Title
Reduction in Total Passive Extension Deficit
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Quick Dash (Disabilities of the shoulder and Hand)
Time Frame
5 years
Title
EQ5D (Euroqol 5 Dimensions)
Time Frame
5 years
Title
Brief MHQ (Michigan Hand Questionare)
Time Frame
5 years
Title
URAM (Unité Rhumatologique des Affections de la Main)
Time Frame
5 years
Title
Jamar grip strength
Time Frame
1,4,26 weeks and one year.
Title
VAS (Visual analogue scale) pain
Description
0 is no pain, 10 maximum pain
Time Frame
1,4,26 weeks and one year
Title
VAS (Visual analogue sale) satisfaction
Description
0 is not satisfied, 10 maximum satisfied
Time Frame
1,4,26 weeks. 1,2 and 5 years
Title
Complications
Description
AE,SAE,SUSAR
Time Frame
1,4,weeks One year
Title
Recurrence
Description
def. 30 degrees of treated MCP joint, or 20 or more degrees of adjecent PIPJ
Time Frame
1,4,26 weeks. 1,2 and 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Primary Dd disease (no earlier treatment for this condition of the hand involved) Single digit involvement, one of the three ulnar digits Average norwegian language skills. MCPJ contracture of 30 degrees or more and less than 20 degree involvement of the adjacent PIPJ Minimum 18 y.o. Exclusion Criteria: Involvement of 2 fingers/joints Earlier treatment for Dd disease of the same hand, affection of addjecent PIPJ of 20 degrees or mor Pregnancy Ongoing treatment with platelet inhibitors Treatment with tetracycline 2 weeks prior to treatment date Poor norwegian language skills Participation in other studies 4 weeks prior or after treatment date "Need to treat" of both hands
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per-Henrik Randsborg, PhD
Organizational Affiliation
University Hospital, Akershus
Official's Role
Study Director
Facility Information:
Facility Name
Akershus University Hospital
City
Oslo
State/Province
Akershus
ZIP/Postal Code
1478
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF

We'll reach out to this number within 24 hrs